Loading…
Evaluation of the resistance patterns of Mycobacterium tuberculosis complex strains to antituberculous drugs
Aim: To determine the resistance profile of Mycobacterium tuberculosis complex (MTBC) strains to first-line antituberculous drugs. Methods: A total of 138 patients with MTBC growth from 2008-2018 were evaluated retrospectively. The Ehrlich-Ziehl-Neelsen (EZN) staining method was used for direct smea...
Saved in:
| Published in: | Experimental biomedical research 2019-10, Vol.2 (4), p.143-148 |
|---|---|
| Main Authors: | , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c2183-bca835f89b5843ce8790966e5d9e37ad5eab8e8db84a73829c0b6a5bfbaf1a1f3 |
|---|---|
| cites | |
| container_end_page | 148 |
| container_issue | 4 |
| container_start_page | 143 |
| container_title | Experimental biomedical research |
| container_volume | 2 |
| creator | Karabork, Seyda Avcioglu, Fatma Karaibrahim, Ayse Kurtoglu, Muhammet Guzel Behcet, Mustafa |
| description | Aim: To determine the resistance profile of Mycobacterium tuberculosis complex (MTBC) strains to
first-line antituberculous drugs.
Methods: A total of 138 patients with MTBC growth from 2008-2018 were evaluated retrospectively.
The Ehrlich-Ziehl-Neelsen (EZN) staining method was used for direct smear preparations, the
BACTEC MGIT 460 TB system the Lowenstein-Jensen medium for culture planting and the
BACTEC NAP test for the diagnosis of MTBC. Susceptibility tests were performed using the
BACTEC MGIT 460 TB system with the streptomycin, isoniazid, rifampicin and ethambutol (SIRE)
kit in accordance with the manufacturer's recommendations.
Results: Of the total 138 tuberculosis (TB) cases, 44 (31.9%) were female and 94 (68.1%) were male.
MTBC was most frequently isolated from pulmonary specimens (90.6%). Acid-resistant bacilli
(ARB) positivity was detected in 88 (63.8%) samples by EZN staining for culture-positive samples.
In our study, without considering single or multiple drug resistance (MDR), total resistance rates in
MTBC strains were determined for, isoniazid (INH), rifampicin (RIF), ethambutol (EMB), and
streptomycin (SM); 10.1%, 4.3%, 2.9%, and 12.3% respectively. While the susceptibility to all drugs
was 82.6%, multiple drug–resistant tuberculosis (MDR-TB) was 2.9%.
Conclusion: These results are important since they are the first data reported from our province
regarding the determination of the resistance profile to anti-TB drugs. Resistance rates in our study
were very close to the 2016 data average of the Ministry of Health of Turkey. Determination of TB
resistance profiles, as well as proper and regular treatment, will contribute to the control of MDRTB. |
| doi_str_mv | 10.30714/j-ebr.2019454842 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_ideal</sourceid><recordid>TN_cdi_proquest_journals_2371714163</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2371714163</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2183-bca835f89b5843ce8790966e5d9e37ad5eab8e8db84a73829c0b6a5bfbaf1a1f3</originalsourceid><addsrcrecordid>eNpN0ctKAzEUBuBBFCzaB3AXcONmajKZS2ZZatVCxY2uw0nmjM4wndRcxL69sRXrKufnfCSQP0muGJ1xWrH8tk9R2VlGWZ0Xucizk2SSlUykZYyn_-bzZOpcTynNRJVTRifJsPyEIYDvzEhMS_w7Eouucx5GjWQL3qMd3c_qaaeNAh1zFzbEB4VWh8FES7TZbAf8Is5b6KL2hsDouz8THGlseHOXyVkLg8Pp73mRvN4vXxaP6fr5YbWYr1OdMcFTpUHwohW1KkTONYqqpnVZYtHUyCtoCgQlUDRK5FBxkdWaqhIK1SpoGbCWXyTXh3u31nwEdF72JtgxPikzXrH4Y6zkUd0cVNcgDGYcuhGPcHW3nK8lo3m5p-xAtTXOWWzl1nYbsLsI5L4C2ctYgTxWwL8B8Rx85w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2371714163</pqid></control><display><type>article</type><title>Evaluation of the resistance patterns of Mycobacterium tuberculosis complex strains to antituberculous drugs</title><source>Publicly Available Content Database (Proquest) (PQ_SDU_P3)</source><creator>Karabork, Seyda ; Avcioglu, Fatma ; Karaibrahim, Ayse ; Kurtoglu, Muhammet Guzel ; Behcet, Mustafa</creator><contributor>Öztürk,Hayrettin</contributor><creatorcontrib>Karabork, Seyda ; Avcioglu, Fatma ; Karaibrahim, Ayse ; Kurtoglu, Muhammet Guzel ; Behcet, Mustafa ; Öztürk,Hayrettin</creatorcontrib><description>Aim: To determine the resistance profile of Mycobacterium tuberculosis complex (MTBC) strains to
first-line antituberculous drugs.
Methods: A total of 138 patients with MTBC growth from 2008-2018 were evaluated retrospectively.
The Ehrlich-Ziehl-Neelsen (EZN) staining method was used for direct smear preparations, the
BACTEC MGIT 460 TB system the Lowenstein-Jensen medium for culture planting and the
BACTEC NAP test for the diagnosis of MTBC. Susceptibility tests were performed using the
BACTEC MGIT 460 TB system with the streptomycin, isoniazid, rifampicin and ethambutol (SIRE)
kit in accordance with the manufacturer's recommendations.
Results: Of the total 138 tuberculosis (TB) cases, 44 (31.9%) were female and 94 (68.1%) were male.
MTBC was most frequently isolated from pulmonary specimens (90.6%). Acid-resistant bacilli
(ARB) positivity was detected in 88 (63.8%) samples by EZN staining for culture-positive samples.
In our study, without considering single or multiple drug resistance (MDR), total resistance rates in
MTBC strains were determined for, isoniazid (INH), rifampicin (RIF), ethambutol (EMB), and
streptomycin (SM); 10.1%, 4.3%, 2.9%, and 12.3% respectively. While the susceptibility to all drugs
was 82.6%, multiple drug–resistant tuberculosis (MDR-TB) was 2.9%.
Conclusion: These results are important since they are the first data reported from our province
regarding the determination of the resistance profile to anti-TB drugs. Resistance rates in our study
were very close to the 2016 data average of the Ministry of Health of Turkey. Determination of TB
resistance profiles, as well as proper and regular treatment, will contribute to the control of MDRTB.</description><identifier>ISSN: 2618-6454</identifier><identifier>EISSN: 2618-6454</identifier><identifier>DOI: 10.30714/j-ebr.2019454842</identifier><language>eng</language><publisher>Bolu: Prof. Dr. Hayrettin Öztürk</publisher><subject>Bacilli ; Drug resistance ; Drugs ; Ethambutol ; Isoniazid ; Multidrug resistance ; Mycobacterium tuberculosis ; Rifampin ; Sağlık Hizmetleri ; Streptomycin ; Tıp ; Tuberculosis</subject><ispartof>Experimental biomedical research, 2019-10, Vol.2 (4), p.143-148</ispartof><rights>2019. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c2183-bca835f89b5843ce8790966e5d9e37ad5eab8e8db84a73829c0b6a5bfbaf1a1f3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/2371714163?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,25753,27924,27925,37012,44590</link.rule.ids></links><search><contributor>Öztürk,Hayrettin</contributor><creatorcontrib>Karabork, Seyda</creatorcontrib><creatorcontrib>Avcioglu, Fatma</creatorcontrib><creatorcontrib>Karaibrahim, Ayse</creatorcontrib><creatorcontrib>Kurtoglu, Muhammet Guzel</creatorcontrib><creatorcontrib>Behcet, Mustafa</creatorcontrib><title>Evaluation of the resistance patterns of Mycobacterium tuberculosis complex strains to antituberculous drugs</title><title>Experimental biomedical research</title><description>Aim: To determine the resistance profile of Mycobacterium tuberculosis complex (MTBC) strains to
first-line antituberculous drugs.
Methods: A total of 138 patients with MTBC growth from 2008-2018 were evaluated retrospectively.
The Ehrlich-Ziehl-Neelsen (EZN) staining method was used for direct smear preparations, the
BACTEC MGIT 460 TB system the Lowenstein-Jensen medium for culture planting and the
BACTEC NAP test for the diagnosis of MTBC. Susceptibility tests were performed using the
BACTEC MGIT 460 TB system with the streptomycin, isoniazid, rifampicin and ethambutol (SIRE)
kit in accordance with the manufacturer's recommendations.
Results: Of the total 138 tuberculosis (TB) cases, 44 (31.9%) were female and 94 (68.1%) were male.
MTBC was most frequently isolated from pulmonary specimens (90.6%). Acid-resistant bacilli
(ARB) positivity was detected in 88 (63.8%) samples by EZN staining for culture-positive samples.
In our study, without considering single or multiple drug resistance (MDR), total resistance rates in
MTBC strains were determined for, isoniazid (INH), rifampicin (RIF), ethambutol (EMB), and
streptomycin (SM); 10.1%, 4.3%, 2.9%, and 12.3% respectively. While the susceptibility to all drugs
was 82.6%, multiple drug–resistant tuberculosis (MDR-TB) was 2.9%.
Conclusion: These results are important since they are the first data reported from our province
regarding the determination of the resistance profile to anti-TB drugs. Resistance rates in our study
were very close to the 2016 data average of the Ministry of Health of Turkey. Determination of TB
resistance profiles, as well as proper and regular treatment, will contribute to the control of MDRTB.</description><subject>Bacilli</subject><subject>Drug resistance</subject><subject>Drugs</subject><subject>Ethambutol</subject><subject>Isoniazid</subject><subject>Multidrug resistance</subject><subject>Mycobacterium tuberculosis</subject><subject>Rifampin</subject><subject>Sağlık Hizmetleri</subject><subject>Streptomycin</subject><subject>Tıp</subject><subject>Tuberculosis</subject><issn>2618-6454</issn><issn>2618-6454</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><recordid>eNpN0ctKAzEUBuBBFCzaB3AXcONmajKZS2ZZatVCxY2uw0nmjM4wndRcxL69sRXrKufnfCSQP0muGJ1xWrH8tk9R2VlGWZ0Xucizk2SSlUykZYyn_-bzZOpcTynNRJVTRifJsPyEIYDvzEhMS_w7Eouucx5GjWQL3qMd3c_qaaeNAh1zFzbEB4VWh8FES7TZbAf8Is5b6KL2hsDouz8THGlseHOXyVkLg8Pp73mRvN4vXxaP6fr5YbWYr1OdMcFTpUHwohW1KkTONYqqpnVZYtHUyCtoCgQlUDRK5FBxkdWaqhIK1SpoGbCWXyTXh3u31nwEdF72JtgxPikzXrH4Y6zkUd0cVNcgDGYcuhGPcHW3nK8lo3m5p-xAtTXOWWzl1nYbsLsI5L4C2ctYgTxWwL8B8Rx85w</recordid><startdate>20191001</startdate><enddate>20191001</enddate><creator>Karabork, Seyda</creator><creator>Avcioglu, Fatma</creator><creator>Karaibrahim, Ayse</creator><creator>Kurtoglu, Muhammet Guzel</creator><creator>Behcet, Mustafa</creator><general>Prof. Dr. Hayrettin Öztürk</general><general>Experimental Biomedical Research</general><scope>AAYXX</scope><scope>CITATION</scope><scope>IEBAR</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20191001</creationdate><title>Evaluation of the resistance patterns of Mycobacterium tuberculosis complex strains to antituberculous drugs</title><author>Karabork, Seyda ; Avcioglu, Fatma ; Karaibrahim, Ayse ; Kurtoglu, Muhammet Guzel ; Behcet, Mustafa</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2183-bca835f89b5843ce8790966e5d9e37ad5eab8e8db84a73829c0b6a5bfbaf1a1f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Bacilli</topic><topic>Drug resistance</topic><topic>Drugs</topic><topic>Ethambutol</topic><topic>Isoniazid</topic><topic>Multidrug resistance</topic><topic>Mycobacterium tuberculosis</topic><topic>Rifampin</topic><topic>Sağlık Hizmetleri</topic><topic>Streptomycin</topic><topic>Tıp</topic><topic>Tuberculosis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Karabork, Seyda</creatorcontrib><creatorcontrib>Avcioglu, Fatma</creatorcontrib><creatorcontrib>Karaibrahim, Ayse</creatorcontrib><creatorcontrib>Kurtoglu, Muhammet Guzel</creatorcontrib><creatorcontrib>Behcet, Mustafa</creatorcontrib><collection>CrossRef</collection><collection>Idealonline online kütüphane - Journals</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Health and Medical</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection (Proquest) (PQ_SDU_P3)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>ProQuest Biological Science Journals</collection><collection>Publicly Available Content Database (Proquest) (PQ_SDU_P3)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Experimental biomedical research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Karabork, Seyda</au><au>Avcioglu, Fatma</au><au>Karaibrahim, Ayse</au><au>Kurtoglu, Muhammet Guzel</au><au>Behcet, Mustafa</au><au>Öztürk,Hayrettin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Evaluation of the resistance patterns of Mycobacterium tuberculosis complex strains to antituberculous drugs</atitle><jtitle>Experimental biomedical research</jtitle><date>2019-10-01</date><risdate>2019</risdate><volume>2</volume><issue>4</issue><spage>143</spage><epage>148</epage><pages>143-148</pages><issn>2618-6454</issn><eissn>2618-6454</eissn><abstract>Aim: To determine the resistance profile of Mycobacterium tuberculosis complex (MTBC) strains to
first-line antituberculous drugs.
Methods: A total of 138 patients with MTBC growth from 2008-2018 were evaluated retrospectively.
The Ehrlich-Ziehl-Neelsen (EZN) staining method was used for direct smear preparations, the
BACTEC MGIT 460 TB system the Lowenstein-Jensen medium for culture planting and the
BACTEC NAP test for the diagnosis of MTBC. Susceptibility tests were performed using the
BACTEC MGIT 460 TB system with the streptomycin, isoniazid, rifampicin and ethambutol (SIRE)
kit in accordance with the manufacturer's recommendations.
Results: Of the total 138 tuberculosis (TB) cases, 44 (31.9%) were female and 94 (68.1%) were male.
MTBC was most frequently isolated from pulmonary specimens (90.6%). Acid-resistant bacilli
(ARB) positivity was detected in 88 (63.8%) samples by EZN staining for culture-positive samples.
In our study, without considering single or multiple drug resistance (MDR), total resistance rates in
MTBC strains were determined for, isoniazid (INH), rifampicin (RIF), ethambutol (EMB), and
streptomycin (SM); 10.1%, 4.3%, 2.9%, and 12.3% respectively. While the susceptibility to all drugs
was 82.6%, multiple drug–resistant tuberculosis (MDR-TB) was 2.9%.
Conclusion: These results are important since they are the first data reported from our province
regarding the determination of the resistance profile to anti-TB drugs. Resistance rates in our study
were very close to the 2016 data average of the Ministry of Health of Turkey. Determination of TB
resistance profiles, as well as proper and regular treatment, will contribute to the control of MDRTB.</abstract><cop>Bolu</cop><pub>Prof. Dr. Hayrettin Öztürk</pub><doi>10.30714/j-ebr.2019454842</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2618-6454 |
| ispartof | Experimental biomedical research, 2019-10, Vol.2 (4), p.143-148 |
| issn | 2618-6454 2618-6454 |
| language | eng |
| recordid | cdi_proquest_journals_2371714163 |
| source | Publicly Available Content Database (Proquest) (PQ_SDU_P3) |
| subjects | Bacilli Drug resistance Drugs Ethambutol Isoniazid Multidrug resistance Mycobacterium tuberculosis Rifampin Sağlık Hizmetleri Streptomycin Tıp Tuberculosis |
| title | Evaluation of the resistance patterns of Mycobacterium tuberculosis complex strains to antituberculous drugs |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T02%3A38%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_ideal&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Evaluation%20of%20the%20resistance%20patterns%20of%20Mycobacterium%20tuberculosis%20complex%20strains%20to%20antituberculous%20drugs&rft.jtitle=Experimental%20biomedical%20research&rft.au=Karabork,%20Seyda&rft.date=2019-10-01&rft.volume=2&rft.issue=4&rft.spage=143&rft.epage=148&rft.pages=143-148&rft.issn=2618-6454&rft.eissn=2618-6454&rft_id=info:doi/10.30714/j-ebr.2019454842&rft_dat=%3Cproquest_ideal%3E2371714163%3C/proquest_ideal%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c2183-bca835f89b5843ce8790966e5d9e37ad5eab8e8db84a73829c0b6a5bfbaf1a1f3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2371714163&rft_id=info:pmid/&rfr_iscdi=true |